Lung Cancer Screening and the Role of the
Pulmonary Nodule Navigator (Non-Physician) Test
Lung cancer is the leading cause of cancer death for men and women and in the US more people die of lung cancer each year than of colon, breast and prostate cancer combined. Are you familiar with the latest recommendations for lung cancer screening? Which patients need to be screened? How do you talk with patients about the uncertainties associated with lung cancer screening? Hear from two experts on these subjects related to lung cancer best practices.
Upon completion of this activity, participants will be able to:
Describe appropriate screenings for lung cancers
Articulate the importance of documenting discussions with patients about screening and results of screening
Discuss building a Pulmonary Navigator program, a Quality Improvement initiative created by CRICO-insured physicians to improve screening for lung cancer
Gerald Smetana, MD, Professor of Medicine, Harvard Medical School; Division of General Medicine and Primary Care, Beth Israel Medical Center
M. Christian Semine, MD, Chair, Department of Radiology, NSMC
Marc B. Garnick, MD, Gorman Brothers Clinical Professor of Medicine, Harvard Medical School; Editor in Chief, HMS Annual Report on Prostate Diseases/HHP and www.HarvardProstateKnowledge.org; Genitourinary Medical Oncologist in the Cancer Center at BIDMC
Continuing Medical Education
CRICO/Risk Management Foundation of the Harvard Medical Institutions is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CRICO/RMF designates this enduring material for a maximum of 1.0 AMA PRA Category I Credit™
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designed to be suitable for 1.0 hours of Risk Management study in MA.